Structure Encountered

Avenzo Therapeutics

Develops selective small molecule inhibitors and bispecific ADCs for oncology

Avenzo dosed the first patient in its CDK4-plus-CDK2-plus-fulvestrant combination cohort for HR+ breast cancer.

SIGNAL·Phase 1/2 first patient (combo cohort)·CDK4+CDK2+fulvestrant·SCORE 71·02 JUN 2026 · 11:54 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

Structure Avenzo Therapeutics, captured by Voyager

STRUCT. / AVENZO THERAPEUTICS

/ San Diego, California, United States

CAPT. / 02.06.26 11:54:29Z

SIGNAL / 71 / 100

Image relayed by The Biotech Voyager during pass over structure Avenzo Therapeutics. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Avenzo Therapeutics

Coordinates

San Diego, California, United States

Stage

Phase 2

Type

Therapeutics

Modalities

ADC · bispecific · small molecule

Therapeutic area

Oncology

002Signature Detected

EVENT DETECTED

Event type

Phase 1/2 first patient (combo cohort)

Magnitude

CDK4+CDK2+fulvestrant

Lead

Avenzo Therapeutics

Participating

ORION-1 (NCT06998407)

003Architecture

PLATFORM PROFILE

Target class

CDK2 (AVZO-021) and CDK4 (AVZO-023), cell-cycle kinases in HR+/HER2- breast cancer. Selective CDK4 spares CDK6-driven blood toxicity; CDK2 blocks the hyperactivation that drives CDK4/6 resistance.

Differentiator

Approved CDK4/6 inhibitors hit CDK6, which bruises the blood, and tumors escape by ramping CDK2. Avenzo split the job: a selective CDK4, a selective CDK2, and fulvestrant together, aiming to dodge the toxicity and close the resistance door at once.

Lead asset

AVZO-021 (CDK2) + AVZO-023 (CDK4), Phase 1/2 ORION-1

Pipeline depth

4 clinical programs: AVZO-021, AVZO-023 (CDK), AVZO-1418, AVZO-103 (bispecific ADCs)

004Voyager Assessment

MACHINE-GENERATED

Two CDK stories in one week, and this is the better-funded one. CDK4/6 inhibitors reshaped HR-positive breast cancer, but CDK6 bruises the blood and tumors escape by cranking up CDK2. Avenzo's answer is to split the target: a selective CDK4, a selective CDK2, and fulvestrant, dosed together for the first time in the ORION-1 combination cohort. The pedigree matters. This is Athena Countouriotis and roughly 45 Turning Point veterans, the team that sold to Bristol Myers Squibb for 4.1 billion dollars. Watch the AVZO-021 update at ASCO 2026 for whether the single agent earns the combination.

005Adjacent Structures

FRONTIER MAP

Alaw Therapeutics· brain-penetrant CDK2/4Blueprint Medicines· BLU-222, CDK2Pfizer· Ibrance / atirmociclibEli Lilly· abemaciclib incumbentGilead Sciences· Trodelvy combo partner

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.